CN103124554A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN103124554A
CN103124554A CN2011800464547A CN201180046454A CN103124554A CN 103124554 A CN103124554 A CN 103124554A CN 2011800464547 A CN2011800464547 A CN 2011800464547A CN 201180046454 A CN201180046454 A CN 201180046454A CN 103124554 A CN103124554 A CN 103124554A
Authority
CN
China
Prior art keywords
composition
composition according
buffer
carbetocin
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800464547A
Other languages
English (en)
Chinese (zh)
Inventor
安德斯·尼尔森
马蒂亚斯·马尔姆
卡齐米日·维希涅夫斯基
布里塔·西克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103124554(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Priority to CN201610930206.3A priority Critical patent/CN107080832B/zh
Priority to CN201510212609.XA priority patent/CN104906032A/zh
Priority to CN201610930541.3A priority patent/CN107412728A/zh
Publication of CN103124554A publication Critical patent/CN103124554A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
CN2011800464547A 2010-09-30 2011-09-29 药物组合物 Pending CN103124554A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201610930206.3A CN107080832B (zh) 2010-09-30 2011-09-29 药物组合物
CN201510212609.XA CN104906032A (zh) 2010-09-30 2011-09-29 药物组合物
CN201610930541.3A CN107412728A (zh) 2010-09-30 2011-09-29 药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10251690.3 2010-09-30
EP10251690 2010-09-30
PCT/IB2011/002394 WO2012042371A2 (en) 2010-09-30 2011-09-29 Pharmaceutical composition

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201610930206.3A Division CN107080832B (zh) 2010-09-30 2011-09-29 药物组合物
CN201510212609.XA Division CN104906032A (zh) 2010-09-30 2011-09-29 药物组合物
CN201610930541.3A Division CN107412728A (zh) 2010-09-30 2011-09-29 药物组合物

Publications (1)

Publication Number Publication Date
CN103124554A true CN103124554A (zh) 2013-05-29

Family

ID=43478408

Family Applications (4)

Application Number Title Priority Date Filing Date
CN2011800464547A Pending CN103124554A (zh) 2010-09-30 2011-09-29 药物组合物
CN201510212609.XA Pending CN104906032A (zh) 2010-09-30 2011-09-29 药物组合物
CN201610930206.3A Active CN107080832B (zh) 2010-09-30 2011-09-29 药物组合物
CN201610930541.3A Pending CN107412728A (zh) 2010-09-30 2011-09-29 药物组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201510212609.XA Pending CN104906032A (zh) 2010-09-30 2011-09-29 药物组合物
CN201610930206.3A Active CN107080832B (zh) 2010-09-30 2011-09-29 药物组合物
CN201610930541.3A Pending CN107412728A (zh) 2010-09-30 2011-09-29 药物组合物

Country Status (27)

Country Link
US (4) US9566311B2 (enExample)
EP (5) EP3222272B1 (enExample)
JP (2) JP6038797B2 (enExample)
KR (2) KR101919119B1 (enExample)
CN (4) CN103124554A (enExample)
AU (1) AU2011309762B2 (enExample)
BR (2) BR112013007362B1 (enExample)
CA (1) CA2812510A1 (enExample)
CY (2) CY1119245T1 (enExample)
DK (4) DK4374878T3 (enExample)
ES (4) ES2637988T3 (enExample)
FI (1) FI4374878T3 (enExample)
HR (3) HRP20211969T1 (enExample)
HU (4) HUE056835T2 (enExample)
IL (3) IL225238B (enExample)
JO (3) JO3400B1 (enExample)
LT (3) LT4374878T (enExample)
MX (3) MX390779B (enExample)
NZ (1) NZ609719A (enExample)
PL (4) PL4374878T3 (enExample)
PT (4) PT3222272T (enExample)
RS (3) RS62873B1 (enExample)
RU (2) RU2737264C2 (enExample)
SI (4) SI3222272T1 (enExample)
SM (3) SMT202200034T1 (enExample)
TW (6) TWI650134B (enExample)
WO (1) WO2012042371A2 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714819A (zh) * 2014-09-19 2017-05-24 辉凌公司 治疗普拉德‑威利综合征的方法
CN107106640A (zh) * 2014-10-01 2017-08-29 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
CN107773531A (zh) * 2016-08-31 2018-03-09 成都倍特药业有限公司 一种马来酸麦角新碱注射液
CN108236601A (zh) * 2016-12-23 2018-07-03 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
CN108721598A (zh) * 2018-07-03 2018-11-02 宋雪萍 一种缩宫素原料的制备方法及其药物组合物和制剂
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
CN111511351A (zh) * 2017-12-22 2020-08-07 艾瑞克有限公司 新型组合物
CN113453661A (zh) * 2018-12-21 2021-09-28 艾瑞克有限公司 新组合物
CN114712483A (zh) * 2022-05-12 2022-07-08 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
UA117912C2 (uk) * 2012-05-08 2018-10-25 Ділафор Аб Застосування гепарину або гепарансульфату для лікування післяпологової кровотечі (ппк)
ES2690140T3 (es) 2014-10-01 2018-11-19 Oxytone Bioscience B.V. Unidad de dosificación farmacéutica sólida de desintegración oral que contiene una sustancia de control del parto
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
WO2019030412A1 (en) * 2017-08-11 2019-02-14 Ferring B.V. PROCESS FOR PRODUCING PHARMACEUTICAL PREPARATION
JP2021515005A (ja) 2018-03-01 2021-06-17 トライジェミナ， インコーポレイテッド 標識オキシトシンならびに製造および使用の方法
CN114288253B (zh) 2018-09-20 2024-04-02 阿卡蒂亚药品公司 稳定的鼻内卡贝缩宫素制剂
KR20210062648A (ko) 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 카르베토신 완제의약품 및 이를 제조하는 방법
CN109745544B (zh) * 2018-11-23 2024-11-08 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用
CA3141488A1 (en) 2019-05-22 2020-11-26 Biovie Inc. Formulations of terlipressin
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
US20220313774A1 (en) 2019-11-04 2022-10-06 Ferring B.V. Intranasal administration of merotocin for improving lactation
AU2022242768A1 (en) 2021-03-26 2023-10-19 Centre Hospitalier Universitaire De Toulouse Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
WO2024211393A2 (en) 2023-04-04 2024-10-10 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001185A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Stabilized pharmaceutical peptide compositions
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DE69736140T2 (de) 1997-11-18 2007-04-19 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
DE60333857D1 (de) 2002-10-03 2010-09-30 Neuropharmacology Services Llc Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
ATE424215T1 (de) 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
CN1938040A (zh) 2003-03-05 2007-03-28 Pr药品有限公司 缩宫素控释制剂及其应用方法
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2009005351A1 (en) 2007-07-02 2009-01-08 Sime Darby Malaysia Berhad Vegetable fat blend and edible products containing such a fat blend
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
SI2260053T1 (sl) * 2008-03-31 2014-08-29 Ferring Bv Analogi oksitocina
CN102281865B (zh) * 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001185A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Stabilized pharmaceutical peptide compositions
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714819A (zh) * 2014-09-19 2017-05-24 辉凌公司 治疗普拉德‑威利综合征的方法
CN112773765A (zh) * 2014-09-19 2021-05-11 辉凌公司 治疗普拉德-威利综合征的方法
CN107106640A (zh) * 2014-10-01 2017-08-29 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
CN107106640B (zh) * 2014-10-01 2021-06-15 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN107773531A (zh) * 2016-08-31 2018-03-09 成都倍特药业有限公司 一种马来酸麦角新碱注射液
CN108236601A (zh) * 2016-12-23 2018-07-03 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
CN111511351A (zh) * 2017-12-22 2020-08-07 艾瑞克有限公司 新型组合物
CN108721598A (zh) * 2018-07-03 2018-11-02 宋雪萍 一种缩宫素原料的制备方法及其药物组合物和制剂
CN113453661A (zh) * 2018-12-21 2021-09-28 艾瑞克有限公司 新组合物
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
CN114712483A (zh) * 2022-05-12 2022-07-08 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途

Also Published As

Publication number Publication date
JP6250770B2 (ja) 2017-12-20
JOP20180103B1 (ar) 2022-03-14
ES2637988T3 (es) 2017-10-18
SI3222272T1 (sl) 2022-01-31
CY1119245T1 (el) 2018-02-14
SI3246018T1 (sl) 2022-02-28
HUE057187T2 (hu) 2022-04-28
BR112013007362A2 (pt) 2016-07-12
JP2017048226A (ja) 2017-03-09
ES3027637T3 (en) 2025-06-16
IL245328B (en) 2022-04-01
PT4374878T (pt) 2025-05-02
PL3222272T3 (pl) 2022-03-07
RS62873B1 (sr) 2022-02-28
SI4374878T1 (sl) 2025-06-30
HRP20211969T1 (hr) 2022-03-18
PL3246018T3 (pl) 2022-05-02
ES2902418T3 (es) 2022-03-28
JP2013543492A (ja) 2013-12-05
HRP20250382T1 (hr) 2025-05-23
HUE056835T2 (hu) 2022-03-28
CY1124924T1 (el) 2023-01-05
US20170106044A1 (en) 2017-04-20
IL245328A0 (en) 2016-06-30
EP2621468B1 (en) 2017-06-14
TW202112389A (zh) 2021-04-01
US20170106043A1 (en) 2017-04-20
JOP20180102A1 (ar) 2019-01-30
CA2812510A1 (en) 2012-04-05
US9566311B2 (en) 2017-02-14
WO2012042371A2 (en) 2012-04-05
TW201605465A (zh) 2016-02-16
EP3222272B1 (en) 2021-11-03
IL245326A0 (en) 2016-06-30
TW201605466A (zh) 2016-02-16
US20230124105A1 (en) 2023-04-20
TWI746951B (zh) 2021-11-21
RU2604690C2 (ru) 2016-12-10
EP3936117A1 (en) 2022-01-12
HRP20171256T1 (hr) 2017-10-20
CN107080832B (zh) 2021-05-07
LT3222272T (lt) 2021-12-27
EP3246018A1 (en) 2017-11-22
DK3246018T3 (da) 2022-01-17
KR101919119B1 (ko) 2018-11-15
HUE070972T2 (hu) 2025-07-28
DK4374878T3 (da) 2025-05-05
JO3400B1 (ar) 2019-10-20
TWI680773B (zh) 2020-01-01
KR20180123599A (ko) 2018-11-16
RS66759B1 (sr) 2025-05-30
IL225238B (en) 2018-07-31
CN107412728A (zh) 2017-12-01
EP4374878A2 (en) 2024-05-29
DK2621468T3 (en) 2017-09-11
ES2905561T3 (es) 2022-04-11
RU2016143751A3 (enExample) 2020-01-16
FI4374878T3 (fi) 2025-05-16
TWI532507B (zh) 2016-05-11
SI2621468T1 (sl) 2017-10-30
AU2011309762B2 (en) 2014-07-17
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
MX2013003365A (es) 2013-07-29
LT2621468T (lt) 2017-11-27
BR112013007362B1 (pt) 2021-05-25
EP3222272A1 (en) 2017-09-27
EP4374878A3 (en) 2024-07-24
JOP20180103A1 (ar) 2019-01-30
SMT202200034T1 (it) 2022-03-21
BR122021001123B1 (pt) 2021-05-18
TWI661834B (zh) 2019-06-11
IL245326B (en) 2021-04-29
PT3246018T (pt) 2022-01-13
SMT202500165T1 (it) 2025-05-12
CN104906032A (zh) 2015-09-16
TW201729797A (zh) 2017-09-01
EP3246018B1 (en) 2021-11-03
US20130210746A1 (en) 2013-08-15
TWI650134B (zh) 2019-02-11
MX352949B (es) 2017-12-15
MX395271B (es) 2025-03-21
PL4374878T3 (pl) 2025-06-09
RU2013112666A (ru) 2014-11-10
KR20130136467A (ko) 2013-12-12
PT2621468T (pt) 2017-09-08
JOP20180102B1 (ar) 2022-03-14
NZ609719A (en) 2014-07-25
SMT201700420T1 (it) 2017-11-15
HUE034367T2 (en) 2018-02-28
RU2737264C2 (ru) 2020-11-26
PL2621468T3 (pl) 2017-11-30
LT4374878T (lt) 2025-04-25
RS56220B1 (sr) 2017-11-30
CN107080832A (zh) 2017-08-22
TW201940188A (zh) 2019-10-16
IL225238A0 (en) 2013-06-27
DK3222272T3 (da) 2022-01-24
EP2621468A2 (en) 2013-08-07
KR102102664B1 (ko) 2020-04-22
MX390779B (es) 2025-03-21
RU2016143751A (ru) 2018-12-18
WO2012042371A3 (en) 2013-04-04
AU2011309762A1 (en) 2013-04-04
EP4374878B1 (en) 2025-02-12
JP6038797B2 (ja) 2016-12-07
TWI750934B (zh) 2021-12-21
HK1246170A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
CN103124554A (zh) 药物组合物
HK40064553A (en) Pharmaceutical composition
HK1181686A (en) Pharmaceutical composition
HK1244442A1 (en) Pharmaceutical composition
HK1246170B (en) Pharmaceutical composition
AU2013204097A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1181686

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130529

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1181686

Country of ref document: HK